257 related articles for article (PubMed ID: 8599870)
1. cis-Diamminedichloroplatinum(II)-induced cell death through apoptosis in sensitive and resistant human ovarian carcinoma cell lines.
Ormerod MG; O'Neill C; Robertson D; Kelland LR; Harrap KR
Cancer Chemother Pharmacol; 1996; 37(5):463-71. PubMed ID: 8599870
[TBL] [Abstract][Full Text] [Related]
2. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
O'Neill CF; Koberle B; Masters JR; Kelland LR
Br J Cancer; 1999 Dec; 81(8):1294-303. PubMed ID: 10604725
[TBL] [Abstract][Full Text] [Related]
3. Cellular pharmacology of cis and trans pairs of platinum complexes in cisplatin-sensitive and -resistant human ovarian carcinoma cells.
O'Neill CF; Hunakova L; Kelland LR
Chem Biol Interact; 1999 Nov; 123(1):11-29. PubMed ID: 10597899
[TBL] [Abstract][Full Text] [Related]
4. Apoptotic and non-apoptotic cell death induced by cis and trans analogues of a novel ammine(cyclohexylamine)dihydroxodichloroplatinum(IV) complex.
O'Neill CF; Ormerod MG; Robertson D; Titley JC; Cumber-Walsweer Y; Kelland LR
Br J Cancer; 1996 Oct; 74(7):1037-45. PubMed ID: 8855971
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin induces apoptosis in a human ovarian carcinoma cell line without concomitant internucleosomal degradation of DNA.
Ormerod MG; O'Neill CF; Robertson D; Harrap KR
Exp Cell Res; 1994 Apr; 211(2):231-7. PubMed ID: 8143768
[TBL] [Abstract][Full Text] [Related]
6. Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates.
Kelland LR; Mistry P; Abel G; Loh SY; O'Neill CF; Murrer BA; Harrap KR
Cancer Res; 1992 Jul; 52(14):3857-64. PubMed ID: 1617660
[TBL] [Abstract][Full Text] [Related]
7. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
Schmidt W; Chaney SG
Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
[TBL] [Abstract][Full Text] [Related]
8. Apoptosis as a measure of chemosensitivity to cisplatin and taxol therapy in ovarian cancer cell lines.
Gibb RK; Taylor DD; Wan T; O'Connor DM; Doering DL; Gerçel-Taylor C
Gynecol Oncol; 1997 Apr; 65(1):13-22. PubMed ID: 9103385
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of acquired resistance to the orally active platinum-based anticancer drug bis-acetato-ammine-dichloro-cyclohexylamine platinum (i.v.) (JM216) in two human ovarian carcinoma cell lines.
Mellish KJ; Kelland LR
Cancer Res; 1994 Dec; 54(23):6194-200. PubMed ID: 7954466
[TBL] [Abstract][Full Text] [Related]
10. Ovarian cancer cisplatin-resistant cell lines: multiple changes including collateral sensitivity to Taxol.
Perego P; Romanelli S; Carenini N; Magnani I; Leone R; Bonetti A; Paolicchi A; Zunino F
Ann Oncol; 1998 Apr; 9(4):423-30. PubMed ID: 9636834
[TBL] [Abstract][Full Text] [Related]
11. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
12. Comparison of cellular accumulation and cytotoxicity of cisplatin with that of tetraplatin and amminedibutyratodichloro(cyclohexylamine)platinum(IV) (JM221) in human ovarian carcinoma cell lines.
Mistry P; Kelland LR; Loh SY; Abel G; Murrer BA; Harrap KR
Cancer Res; 1992 Nov; 52(22):6188-93. PubMed ID: 1423261
[TBL] [Abstract][Full Text] [Related]
13. Anti-proliferative activity and mechanism of action of titanocene dichloride.
Christodoulou CV; Eliopoulos AG; Young LS; Hodgkins L; Ferry DR; Kerr DJ
Br J Cancer; 1998 Jun; 77(12):2088-97. PubMed ID: 9649119
[TBL] [Abstract][Full Text] [Related]
14. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV).
Hagopian GS; Mills GB; Khokhar AR; Bast RC; Siddik ZH
Clin Cancer Res; 1999 Mar; 5(3):655-63. PubMed ID: 10100719
[TBL] [Abstract][Full Text] [Related]
15. In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473.
Holford J; Sharp SY; Murrer BA; Abrams M; Kelland LR
Br J Cancer; 1998; 77(3):366-73. PubMed ID: 9472630
[TBL] [Abstract][Full Text] [Related]
16. Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance.
Sharp SY; Rogers PM; Kelland LR
Clin Cancer Res; 1995 Sep; 1(9):981-9. PubMed ID: 9816070
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of action of an orally administered platinum complex [ammine bis butyrato cyclohexylamine dichloroplatinum (IV) (JM221)] in intrinsically cisplatin-resistant human ovarian carcinoma in vitro.
McKeage MJ; Abel G; Kelland LR; Harrap KR
Br J Cancer; 1994 Jan; 69(1):1-7. PubMed ID: 8286188
[TBL] [Abstract][Full Text] [Related]
18. Induction and repair of DNA double-strand breaks using constant-field gel electrophoresis and apoptosis as predictive markers for sensitivity of cancer cells to cisplatin.
Saleh EM; El-Awady RA; Anis N; El-Sharkawy N
Biomed Pharmacother; 2012 Oct; 66(7):554-62. PubMed ID: 22939736
[TBL] [Abstract][Full Text] [Related]
19. Correlation between cell killing by cis-diamminedichloroplatinum(II) in six mammalian cell lines and binding of a cis-diamminedichloroplatinum(II)-DNA antiserum.
Terheggen PM; Emondt JY; Floot BG; Dijkman R; Schrier PI; den Engelse L; Begg AC
Cancer Res; 1990 Jun; 50(12):3556-61. PubMed ID: 2340504
[TBL] [Abstract][Full Text] [Related]
20. BCL-2 family protein expression and platinum drug resistance in ovarian carcinoma.
Beale PJ; Rogers P; Boxall F; Sharp SY; Kelland LR
Br J Cancer; 2000 Jan; 82(2):436-40. PubMed ID: 10646901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]